A Phase 2a/b, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicenter, Clinical Study to Evaluate the Efficacy and Safety of OG-6219 in 3 Dose Levels, in Women 18 to 49 Years of Age with Moderate to Severe Endometriosis-related Pain

Date Added
July 5th, 2023
PRO Number
Pro00129682
Researcher
David Soper

List of Studies


Keywords
Obstetrics and Gynecology
Summary

The purpose of this global study is to determine the efficacy, safety, and tolerability of 3 dose levels of OG-6219 (50, 100, and 150 mg twice a day [BID]) in pre-menopausal women between 18 and 49 years of age (inclusive), who have moderate to severe endometriosis-related pain.

Institution
MUSC
Recruitment Contact
Jesslyn Payne
843-792-7525
paynej@musc.edu



-- OR --